Agios Pharmaceuticals, Inc. (AGIO) DCF Valuation

Agios Pharmaceuticals, Inc. (AGIO) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Agios Pharmaceuticals, Inc. (AGIO) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Explore Agios Pharmaceuticals, Inc. (AGIO) financial future with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate Agios Pharmaceuticals, Inc. (AGIO) intrinsic value and shape your investment approach.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue 117.9 203.2 .0 14.2 26.8 30.9 35.6 41.0 47.2 54.4
Revenue Growth, % 0 72.33 -100 0 88.36 15.17 15.17 15.17 15.17 15.17
EBITDA -394.9 -326.1 -337.7 -380.5 -384.9 -18.5 -21.3 -24.6 -28.3 -32.6
EBITDA, % -334.87 -160.5 100 -2671.93 -1434.83 -60 -60 -60 -60 -60
Depreciation 16.6 18.8 18.8 18.6 6.6 15.3 17.6 20.3 23.4 27.0
Depreciation, % 14.09 9.24 100 130.33 24.69 49.6 49.6 49.6 49.6 49.6
EBIT -411.5 -344.9 -356.5 -399.0 -391.5 -18.5 -21.3 -24.6 -28.3 -32.6
EBIT, % -348.97 -169.74 100 -2802.26 -1459.52 -60 -60 -60 -60 -60
Total Cash 564.9 670.5 1,286.4 1,097.0 776.9 30.9 35.6 41.0 47.2 54.4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables 15.3 .0 4.4 2.2 2.8
Account Receivables, % 12.99 0 100 15.49 10.48
Inventories 7.3 14.7 16.2 8.5 19.1 15.1 17.4 20.0 23.1 26.5
Inventories, % 6.22 7.23 100 59.63 71.12 48.84 48.84 48.84 48.84 48.84
Accounts Payable 21.9 17.7 16.7 18.6 9.8 16.3 18.8 21.6 24.9 28.7
Accounts Payable, % 18.57 8.72 100 130.73 36.46 52.75 52.75 52.75 52.75 52.75
Capital Expenditure -12.2 -14.9 -5.7 -4.9 -1.0 -3.4 -4.0 -4.6 -5.3 -6.1
Capital Expenditure, % -10.32 -7.34 100 -34.28 -3.72 -11.13 -11.13 -11.13 -11.13 -11.13
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -396.6 -353.2 1,604.7 -128.3 -391.5 -12.2 -14.0 -16.2 -18.6 -21.4
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -392.9 -345.5 1,610.9 -102.9 -405.9 4.4 -1.5 -1.7 -1.9 -2.2
WACC, % 7.86 7.86 7.7 7.75 7.86 7.81 7.81 7.81 7.81 7.81
PV UFCF
SUM PV UFCF -1.4
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) -2
Terminal Value -39
Present Terminal Value -27
Enterprise Value -28
Net Debt -16
Equity Value -12
Diluted Shares Outstanding, MM 56
Equity Value Per Share -0.22

What You Will Get

  • Comprehensive AGIO Financials: Access to historical and projected data for precise valuation.
  • Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
  • Dynamic Calculations: Intrinsic value and NPV are computed automatically.
  • Scenario Analysis: Evaluate various scenarios to assess Agios Pharmaceuticals' future performance.
  • User-Friendly Design: Designed for professionals while remaining approachable for newcomers.

Key Features

  • Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Agios Pharmaceuticals, Inc. (AGIO).
  • WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to AGIO.
  • Customizable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates for accurate projections.
  • Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Agios Pharmaceuticals, Inc. (AGIO).
  • Interactive Dashboard and Charts: Visual representations provide a summary of key valuation metrics for straightforward analysis.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered Agios Pharmaceuticals data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for Agios Pharmaceuticals’ intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose This Calculator for Agios Pharmaceuticals, Inc. (AGIO)?

  • Designed for Industry Experts: A sophisticated tool utilized by researchers, financial analysts, and healthcare consultants.
  • Comprehensive Data: Agios's historical and projected financials are preloaded for enhanced precision.
  • Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
  • Transparent Results: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly Interface: Step-by-step guidance simplifies the calculation process.

Who Should Use This Product?

  • Investors: Evaluate Agios Pharmaceuticals' valuation before making investment decisions.
  • CFOs and Financial Analysts: Optimize valuation processes and assess financial forecasts.
  • Startup Founders: Understand the valuation strategies of established biotech companies like Agios.
  • Consultants: Provide detailed valuation reports and insights for clients in the pharmaceutical sector.
  • Students and Educators: Utilize real-world data from Agios to learn and teach valuation methodologies.

What the Template Contains

  • Comprehensive DCF Model: Editable template with detailed valuation calculations tailored for Agios Pharmaceuticals, Inc. (AGIO).
  • Real-World Data: Agios Pharmaceuticals' historical and projected financials preloaded for thorough analysis.
  • Customizable Parameters: Adjust WACC, growth rates, and tax assumptions to explore various scenarios.
  • Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into Agios Pharmaceuticals' performance.
  • Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Agios Pharmaceuticals, Inc. (AGIO).
  • Dashboard with Visual Outputs: Charts and tables that provide clear, actionable results for informed decision-making.

Es wurden keine passenden Produkte gefunden.